Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.31 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374979 | 0.76 | ALDH1A1 (0.33) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL2073990 | 0.74 | HTR2A (0.36) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL15010759 | 0.74 | POLB (0.33) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL1375450 | 0.74 | NPC1 (0.35) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL553792 | 0.74 | NPC1 (0.35) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL1198917 | 0.74 | ALDH1A1 (0.36) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL10785337 | 0.72 | POLB (0.33) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL461238 | 0.71 | CA2 (0.35) | HTR2AALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3266678 | 0.71 | MEN1 (0.41) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2734403 | 0.71 | NPC1 (0.37) | HTR2AALDH1A1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | claimed |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-12-07 | — | — | US | disclosed |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO., LTD. | 2021-03-25 | — | — | US | disclosed |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-10-29 | — | — | US | disclosed |
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2018-09-20 | — | — | US | disclosed |
| US-9987259-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-06-05 | — | — | US | disclosed |
| EP-2668185-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-11-23 | — | — | EP | disclosed |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-06-16 | — | — | US | disclosed |
| US-9271976-B2 | Pharmaceutical composition comprising pyridone derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | disclosed |
| EP-2970199-A1 | ISOQUINOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-1035114-B1 | Processes for the preparation of nitrogen-heterocyclic compounds | TOSOH CORP (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003013523-A1 | SH3 PROTEIN DOMAINS AND THEIR LIGANDS | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| US-6346621-B1 | INDOLE OR QUINOLINE COMPOUNDS SUBSTITUTED WITH AMINO COMPOUNDS ON NITROGEN | TOSOH CORPORATION (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-1035114-A2 | Nitrogen-heterocyclic compounds and process for production thereof | TOSOH CORPORATION (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0470578-B1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KK (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5399553-A | Oral absorbability | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5254685-A | Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990005523-A2 | PHENANTHROLINEDICARBOXYLATE ESTERS, 4-AMINOQUINOLINE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263965-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | HTR2A 240/4885ALDH1A1 2259/4885HPGD 156/4885 |
| US-20230390259-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | HTR2A 240/4885ALDH1A1 2259/4885HPGD 156/4885 |
| US-20160166552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PIR | HTR2A 240/4885ALDH1A1 2259/4885HPGD 156/4885 |
| US-10456385-B2 | Pharmaceutical composition comprising pyridone derivatives | PLPBP, PDXK, PIR | HTR2A 240/4885ALDH1A1 2259/4885HPGD 156/4885 |
| US-20210085658-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES | PLPBP, PDXK, PNPO | HTR2A 217/4885ALDH1A1 2119/4885HPGD 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.